Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $12M (up 5880.3% year over year) with net income of −$50M.
Q2 2026 key financials · XBRL
- Revenue
- $12M
- +5880.3% YoY · +84.2% QoQ
- Net income
- −$50M
- −58.8% YoY · −23.0% QoQ
- Operating margin
- -532.7%
- EPS (diluted)
- −$0.90
- −1.1% YoY · −5.9% QoQ
Source: XBRL data from the Dianthus Therapeutics, Inc. /DE/ (DNTH) Q2 2026 10-Q on SEC EDGAR. USD.
Dianthus Therapeutics, Inc. /DE/ Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes identified; filing incorporates 2025 Form 10-K risk factors
- Business risk: Unspecified carried-forward risks could materially harm growth prospects and financial condition
- Market risk: Adverse developments could reduce Dianthus common-stock market price
- Disclosure risk: Additional currently unknown or immaterial risks may harm operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dianthus Therapeutics, Inc. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.